Table 3. Association between the expression level of lnc-RAB11B-AS1 and the prognosis of the lung cancer patients.
| Variables | lnc-RAB11B-AS1 lowly expressed | lnc-RAB11B-AS1 highly expressed | Adjusted HR (95% CI)a | Phomob | Pinterc | |||
|---|---|---|---|---|---|---|---|---|
| Case N | Death, N (%) | Case, N | Death, N (%) | |||||
| Age | ||||||||
| <60 | 28 | 13 (46.4) | 70 | 64 (91.4) | 2.58 (1.42–4.71) | 0.361 | 0.362 | |
| ≥60 | 23 | 16 (69.6) | 42 | 40 (95.2) | 1.74 (0.96–3.16) | |||
| Sex | ||||||||
| Female | 25 | 16 (64.0) | 29 | 26 (89.7) | 2.02 (1.12–3.65) | 0.742 | 0.712 | |
| Male | 26 | 13 (50.0) | 83 | 78 (94.0) | 2.34 (1.23–4.46) | |||
| Family history of cancer | ||||||||
| No | 45 | 24 (53.3) | 100 | 93 (93.0) | 2.40 (1.52–3.78) | 0.227 | 0.112 | |
| Yes | 6 | 5 (83.3) | 12 | 11 (91.7) | 1.15 (0.38–3.46) | |||
| Family history of lung cancer | ||||||||
| No | 49 | 27 (55.1) | 108 | 100 (92.3) | 2.20 (1.43–3.38) | 0.417 | 0.760 | |
| Yes | 2 | 2 (100.0) | 4 | 4 (100.0) | 65.32 (0.02-251377) | |||
| Smoking | ||||||||
| No | 30 | 17 (56.7) | 34 | 30 (88.2) | 2.45 (1.32–4.54) | 0.373 | 0.381 | |
| Yes | 21 | 12 (59.8) | 78 | 74 (94.9) | 1.63 (0.82–3.01) | |||
| Drinking | ||||||||
| No | 43 | 28 (65.1) | 80 | 73 (91.3) | 1.80 (1.16–2.80) | 0.092 | 0.083 | |
| Yes | 8 | 1 (12.5) | 32 | 31 (96.9) | 10.44 (1.42–76.80) | |||
| Stage | ||||||||
| I + II | 32 | 18 (56.3) | 23 | 23 (100.0) | 1.91 (0.86–4.27) | 0.805 | 0.776 | |
| III + IV | 19 | 11 (57.9) | 89 | 81 (91.0) | 2.15 (1.31–3.53) | |||
| Surgery | ||||||||
| No | 35 | 21 (60.0) | 75 | 70 (93.3) | 1.88 (1.15–3.08) | 0.327 | 0.416 | |
| Yes | 16 | 8 (50.0) | 37 | 34 (91.9) | 3.05 (1.33–7.02) | |||
| Chemotherapy | ||||||||
| No | 12 | 10 (83.3) | 40 | 36 (90.0) | 1.20 (0.59–2.47) | 0.094 | 0.100 | |
| Yes | 39 | 19 (48.7) | 72 | 68 (94.4) | 2.55 (1.52–4.27) | |||
| Radiotherapy | ||||||||
| No | 28 | 18 (64.3) | 64 | 62 (96.9) | 2.10 (1.23–3.57) | 0.797 | 0.826 | |
| Yes | 23 | 11 (47.8) | 48 | 42 (87.5) | 2.35 (1.20–4.61) | |||
| Histological types | ||||||||
| Adenocarcinoma | 26 | 14 (53.8) | 50 | 46 (92.0) | 1.98 (1.08–3.62) | 0.967 | 0.411 | |
| Squamous cell carcinoma | 16 | 10 (62.5) | 34 | 33 (97.1) | 2.20 (1.08–4.50) | |||
| Large cell carcinoma | 1 | 1 (100.0) | 4 | 4 (100.0) | – | |||
| Small cell lung cancer | 4 | 2 (50.0) | 11 | 9 (81.2) | 2.80 (0.59–13.31) | |||
| Other carcinomasd | 4 | 2 (50.0) | 13 | 12 (92.3) | 2.66 (0.58–12.15) | |||
a, HRs were adjusted for age, sex, stage and metastasis in a Cox regression model; b, P value of homogeneity test between strata for the related HRs of the lowly expressed and highly expressed lnc-RAB11B-AS1; c, P value of test for the multiplicative interaction between the expression level of lnc-RAB11B-AS1 and selected variables on cancer death in Cox regression models; d, mixed-cell or undifferentiated carcinoma.